{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000015","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.364457+00:00","generated_at":"2026-05-26T03:40:41.246703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Keros Therapeutics Q4 2024 net loss $46.0M; receives $200M Takeda upfront for elritercept","bullets":["Net loss of $46.0M in Q4 2024 vs $40.2M in Q4 2023; full-year net loss $187.4M.","Revenue of $3.0M in Q4 2024 vs $0.1M in prior period, largely from Hansoh milestone.","Cash and equivalents $559.9M at Dec 31, 2024; plus $200M Takeda upfront payment received Feb 2025 extends runway into 2029.","Phase 1 data for KER-065 expected in Q1 2025; Phase 2 TROPOS trial data for cibotercept (KER-012) planned.","R&D expenses rose to $45.6M in Q4 2024, driven by elritercept Phase 3 and TROPOS trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000015","json":"https://secwatch.observer/filing/0001664710-25-000015.json","markdown":"https://secwatch.observer/filing/0001664710-25-000015.md","text":"https://secwatch.observer/filing/0001664710-25-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000015/0001664710-25-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000015/kros-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:40:41.246703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}